Emerfetamab is a half-life extended anti-CD33 x anti-CD3 bispecific T-cell engager (BiTE) antibody. Emerfetamab has been investigated for the treatment of relapsed/_refractory acute myeloid leukemia (AML).
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.